Drug Search Results
More Filters [+]

Naftopidil

Alternative Names: naftopidil
Latest Update: 2024-05-15
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: ADRA1 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: India | Korea | Taiwan

Approved Indications: None

Known Adverse Events: None

Company: Dong-A
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Naftopidil

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Lower Urinary Tract Symptoms|Prostatic Hyperplasia|Ureteral Calculi|Nephrolithiasis|Kidney Calculi|Ureterolithiasis

Phase 3: Pain Unspecified|Lower Urinary Tract Symptoms|Ureterolithiasis|Ureteral Calculi|Prostatic Hyperplasia

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ChiCTR-IPR-15006185

N/A

Recruiting

Ureteral Calculi|Overactive Bladder

2017-09-30

SNUBH-URO-2012-03

P3

Completed

Ureterolithiasis|Ureteral Calculi

2015-08-01

SNUH-URO-2012-04

P3

Completed

Pain Unspecified

2015-06-01

SMC2013-08-066

P4

Unknown status

Ureteral Calculi|Nephrolithiasis|Kidney Calculi|Ureterolithiasis

2015-02-01

Recent News Events